PLS3 and colorectal carcinoma: PLS3 was detectable at significantly lower expression levels in CRC patients compared to IID patients and healthy controls, the latter two groups showing comparable high expression levels (CRC—median: 6.11 [EU], range: 0–34.19 [EU]; IID—median: 22.37 [EU], range: 3.19–179.10 [EU]; healthy—median: 20.48 [EU], range: 7.84–36.59 [EU]; CRC vs. IID p < 0.001; CRC vs. healthy p < 0.001; IID vs. healthy p = ns) (Figure 2B).